Clinical and Laboratory Characteristics of Polycythemia Vera

Conditions

Polycythemia Vera

Brief summary

The study is observational, longitudinal, retrospective and prospective, on patients with PV. Patients with PV diagnosed from 2000 to 2023 according to WHO2017 criteria will be considered. The main purpose of the study is to determine the impact of clinical and laboratory characteristics of Polycythemia Vera on patients' prognosis, understood as long-term survival

Detailed description

The structured collection of data necessary for the evaluation of the objectives will take place through the creation of a specific electronic archive with an expected duration of 7 years, possibly extendable. The electronic archive may be used to review case histories and to obtain or confirm new scientific evidence on Polycythemia Vera. Patients will be followed and treated within the care pathway provided by normal clinical practice. The following elements will be considered in each patient: age, recent and remote pathological history, characteristics of PV onset, histological, cytogenetic and molecular investigations of diagnostic definition, medical therapies performed, type of response to the therapies performed, complications of these therapies and pathology. All useful data will be collected exclusively through consultation of outpatient medical records. The planned enrollment period is 60 months (January 2019-December 2023). The observation period of enrolled patients is at least 2 years.

Francesca Palandri, Alessandra Dedola, Giovanni Caocci, E D Rossi, Elena Maria Elli et al. (27 authors)

Blood Advances2026-06-11

10.1182/bloodadvances.2026020255

Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea

Francesca Palandri, Massimo Breccia, Elena Maria Elli, Roberto Latagliata, Giulia Benevolo et al. (18 authors)

Leukemia2025-05-284 citations

10.1038/s41375-025-02646-y

Revised ELN Criteria in Polycythemia Vera Identify an Increased Risk Phenotype for Thrombotic Events Beyond Conventional Risk Stratification. a Multicenter Cooperative Study

Francesca Palandri, Elena Maria Elli, Giulia Benevolo, Alessandra Dedola, Roberto Latagliata et al. (21 authors)

Blood2024-11-052 citations

10.1182/blood-2024-200528

Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomes.

Palandri F, Branzanti F, Venturi M, Dedola A, Fontana G, Loffredo M, Patuelli A, Ottaviani E, Bersani M, Reta M, Addimanda O, Vicennati V, Vianelli N, Cavo M.

2024-05-213 citations

10.1007/s00277-024-05809-6

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Patients diagnosed with PV according to WHO 2017 criteria, * Obtaining informed consent for data collection and processing

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame	Description
Long-term survival	6 years	To determine the impact of clinical and laboratory characteristics of Polycythemia Vera (PV) on patients' prognosis, in terms of lon term survival

Secondary

Measure	Time frame	Description
Development of second neoplasms	6 years	To assess the incidence of second malignancies
Evolution to acute leukemias	6 years	To assess the incidence of acute leukaemias
Thrombosis	6 years	To assess the incidence of thrombotic events on PV patients
Therapies Efficacy	6 years	To assess the effects of therapies
Therapies	6 years	To assess the use of high-cost therapies
Therapies Toxicity	6 years	To assess the toxicity of therapies
Haemorrhages	6 years	To assess the incidence of haemorrhagic events on PV patients

Countries

Italy

Outcome results